5:38 PM
 | 
Sep 24, 2012
 |  BC Extra  |  Top Story

Peregrine crashes on trial 'discrepancies'

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) plummeted $4.23 (78%) to $1.16 on Monday after discovering "major discrepancies between some patient sample test results and patient treatment code assignments" in a Phase IIb trial of bavituximab for second-line non-small cell lung cancer (NSCLC). Peregrine said...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >